Fresh off its filing for a new COPD drug, Massachusetts-based Sunovion Pharmaceuticals struck a $642 million deal to acquire Toronto-based Cynapsus Therapeutics and its Parkinson’s disease drug candidate.
The U.S. Food and Drug Administration strengthened warnings about the danger of combining opioid painkillers or cough medicines containing opioids with benzodiazepines, a common class of sedatives.
Novartis AG is dissolving its Cell and Gene Therapy Unit, according to Endpoints News, citing a note sent to 400 employees by division president Usman Azam.
Embattled Theranos has run into another testing snag, this time with its proposed blood test for the Zika virus. The company was forced to withdraw its request for emergency clearance of the test after inspectors with the U.S. Food and Drug Administration found the company did not include proper patient protections in its study, according to the Wall Street Journal.
Medivir AB announced that it plans to split up into two independent companies.
Express Scripts Holding, the largest U.S. pharmacy benefit manager, said it will implement a program in 2017 that guarantees per-patient spending caps on diabetes drug costs in an effort to limit soaring increases for its customers.
University of Michigan researchers said their own experiments undermine recent allegations of security flaws in St. Jude Medical Inc.’s pacemakers and other implantable medical devices.
The U.S. Food and Drug Administration approved Novartis AG’s biosimilar version of Amgen Inc.’s arthritis drug Enbrel.
A White Paper from the Community Oncology Alliance (COA) looks at recent moves by Pharmacy Benefit Managers (PBMs) to increase corporate profits by declaring all physician dispensing to be out-of-network.
A California startup has developed a portable technology that will allow consumers to test their food for gluten on the go.